Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 0

The DOI matches its Crossref record; the references it cites are not checked yet.

Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches

Tritos, Nicholas A., Biller, Beverly M. K.·2026·Drugs
DOI 10.1007/s40265-026-02312-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-026-02312-2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Research works printed but not linked: 85

  1. Giustina A, Colao A. Acromegaly. N Engl J Med. 2025;393(19):1926–39. · DOI · Paper page
  2. Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937–50. · DOI · Paper page
  3. Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023;329(16):1386–98. · DOI · Paper page
  4. Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59–71. · DOI · Paper page
  5. Tritos NA, Mattsson AF, Vila G, Biller BMK, Klibanski A, Valluri S, et al. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol. 2020;182(3):285–92. · doi:10.1530/eje-19-0794
  6. Ritvonen E, Loyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer. 2016;23(6):469–80. · DOI · Paper page
  7. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10):3419–26.
  8. Tritos NA, Carlsson MO, Vila G, Jimenez C, La Torre D, Wajnrajch MP, et al. Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Endocr Connect. 2025;14(9):e250247. https://doi.org/10.1530/EC-25-0247. · doi:10.1530/ec-25-0247
  9. Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab. 2012;97(4):1073–81. · DOI
  10. Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51. · DOI · Paper page
  11. Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M, et al. Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol. 2025;21(11):718–37. · DOI · Paper page
  12. Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109–21. · DOI
  13. Falch CM, Dupont AK, Olarescu NC, Wiedmann M, Dahlberg D, Bollerslev J, et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wien). 2023;165(10):3003–10. · doi:10.1007/s00701-023-05772-7
  14. Nunes VS, Correa JM, Puga ME, Silva EM, Boguszewski CL. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary. 2015;18(4):500–8. · DOI
  15. Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022;97(2):333–46. · DOI · Paper page
  16. Shih HA, Loeffler JS. Radiation therapy in acromegaly. Rev Endocr Metab Disord. 2008;9(1):59–65. · DOI
  17. Mathieu D, Kotecha R, Sahgal A, De Salles A, Fariselli L, Pollock BE, et al. Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations. J Neurosurg. 2022;136(3):801–12. · DOI
  18. Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763–835. · DOI · Paper page
  19. Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–33. · DOI · Paper page
  20. Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282–90. · DOI · Paper page
  21. Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. · DOI · Paper page
  22. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE. 2012;7(5):e36411. https://doi.org/10.1371/journal.pone.0036411. · DOI · Paper page
  23. Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31(8):2010–21. · DOI
  24. Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699–708. · DOI · Paper page
  25. Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10(2):102–11. · DOI
  26. Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol. 2015;80(3):460–72. · DOI
  27. Ferone D, Freda P, Katznelson L, Gatto F, Kadioglu P, Maffei P, et al. Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. 2025;110(6):1729–39. · doi:10.1210/clinem/dgae707
  28. Ferone D, Silverstein JM, Freda P, Katznelson L, Gatto F, Kadioglu P, et al. CAM2029, octreotide subcutaneous depot, provides sustained biochemical control of acromegaly: interim results from a phase 3 study (ACROINNOVA 2). J Endocr Soc. 2024;8 (Suppl 1):bvae163.1155. · doi:10.1210/jendso/bvae163.1155
  29. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16. · DOI · Paper page
  30. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9. · DOI · Paper page
  31. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84. · DOI · Paper page
  32. Mondin A, Manara R, Voltan G, Tizianel I, Denaro L, Ferrari M, et al. Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:935759. · DOI
  33. Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, et al. Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett. 2023;14(1):66–74. · DOI
  34. Zhao J, Fu H, Yu J, Hong W, Tian X, Qi J, et al. Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine. Nat Commun. 2023;14(1):962. · DOI
  35. Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab. 2024;110(1):228–37. · doi:10.1210/clinem/dgae385
  36. Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, et al. Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment. J Clin Endocrinol Metab. 2026;111(4):e1050–e1063. https://doi.org/10.1210/clinem/dgaf579. · doi:10.1210/clinem/dgaf579
  37. Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL, et al. IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. J Clin Endocrinol Metab. 2022;107(9):e3644–53. · doi:10.1210/clinem/dgac385
  38. Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P, et al. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol (Lausanne). 2024;15:1250822. · DOI
  39. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53. · DOI · Paper page
  40. Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary. 2021;24(6):887–903. · DOI
  41. Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722–40. · DOI · Paper page
  42. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35. · DOI · Paper page
  43. Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863–8. · DOI
  44. Daftari G, Tritos NA. Impulse control disorders in patients with hyperprolactinemia on dopamine agonist therapy-How concerned should we be? Endocr Pract. 2025;31(7):938–45. · DOI
  45. De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J, et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 2020;105(3):dgz076. https://doi.org/10.1210/clinem/dgz076. · DOI
  46. Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527–34. · DOI
  47. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39–46. · DOI · Paper page
  48. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38. · DOI · Paper page
  49. Stiles CE, Lloyd G, Bhattacharyya S, Steeds RP, Boomla K, Bestwick JP, et al. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab. 2021;106(2):e711–20. · DOI
  50. Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019;90(5):662–9. · DOI
  51. Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur J Endocrinol. 2003;148(Suppl 2):S21–5. · doi:10.1530/eje.0.148s021
  52. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7. · DOI · Paper page
  53. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–9. · DOI · Paper page
  54. Fleseriu M, Fuhrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525–38. · DOI
  55. Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21(3):264–74. · doi:10.4158/ep14330.or
  56. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598–601. · doi:10.1210/jc.2007-1234
  57. Qiao N, He M, Shen M, Zhang Q, Zhang Z, Shou X, et al. Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies. Endocr Pract. 2020;26(4):454–62. · DOI
  58. Colao A, Zgliczynski W, Komorowski J, Kos-Kudla B, Tabarin A, Kerlan V, et al. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynol Pol. 2019;70(4):305–12. · doi:10.5603/ep.a2019.0023
  59. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91. · DOI · Paper page
  60. Tritos NA, Chanson P, Jimenez C, King D, Jonsson PJ, Klibanski A, et al. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol. 2017;176(2):213–20. · doi:10.1530/eje-16-0697
  61. Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2019;104(7):2892–902. · doi:10.1210/jc.2018-02281
  62. Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419–27. · doi:10.1530/eje-18-0616
  63. Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129–35. · doi:10.1007/s11102-016-0753-y
  64. Petersenn S, Houchard A, Sert C, Caron PJ, Group PS. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary. 2020;23(2):171–81. · DOI
  65. Asa SL, Ezzat S. An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism. J Clin Med. 2021;10(11):2254. https://doi.org/10.3390/jcm10112254. · DOI
  66. Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52(2):333–43. · doi:10.1007/s12020-015-0766-8
  67. Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72–8. · doi:10.1111/j.1365-2265.2011.04286.x
  68. Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973–8. · doi:10.1210/jc.2010-0573
  69. Galm BP, Buckless C, Swearingen B, Torriani M, Klibanski A, Bredella MA, et al. MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary. 2020;23(3):212–22. · doi:10.1007/s11102-019-01023-0
  70. Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grange L, Schillo F, et al. Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study. J Clin Endocrinol Metab. 2022;107(11):2982–91. · doi:10.1210/clinem/dgac512
  71. Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, et al. Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2019;104(3):856–62. · DOI
  72. Kocak B, Durmaz ES, Kadioglu P, Polat Korkmaz O, Comunoglu N, Tanriover N, et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731–9. · DOI
  73. Marques-Pamies M, Gil J, Sampedro-Nunez M, Valassi E, Biagetti B, Gimenez-Palop O, et al. Personalized medicine in acromegaly: the ACROFAST study. J Clin Endocrinol Metab. 2024;110(1):30–40. · DOI · Paper page
  74. Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101264. · doi:10.1016/j.beem.2019.02.001
  75. Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, et al. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. 2020;20(1):117. · DOI
  76. Remba-Shapiro I, Schweizer J, Moscona-Nissan A, Liebert KJP, Jones PS, Schilbach K, et al. Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection. Eur J Endocrinol. 2025;193(4):564–73. · doi:10.1093/ejendo/lvaf200
  77. Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. 2020;23(2):140–8. · DOI
  78. Neggers S, Badiu C, Biagetti B, Durand-Gasselin L, Petit A, Petrossians P, et al. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly. Expert Rev Clin Pharmacol. 2021;14(12):1551–60. · doi:10.1080/17512433.2021.1986004
  79. Johnsson M, Pedroncelli AM, Hansson A, Tiberg F. Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide. Endocrine. 2024;84(3):1125–34. · DOI
  80. Shimon I, Rubinek T, Hadani M, Alhadef N. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest. 2004;27(8):721–7. · doi:10.1007/bf03347512
  81. Plockinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in octreotide non-responsive tumours. Eur J Endocrinol. 2012;166(2):223–34. · DOI
  82. Regazzo D, Avallone S, MacSweeney CP, Sergeev E, Howe D, Godwood A, et al. A novel somatostatin receptor ligand for human ACTH- and GH-secreting pituitary adenomas. Eur J Endocrinol. 2024;190(1):K8–16. · DOI
  83. Hata T, Uematsu Y, Sugita A, Adachi H, Kato S, Hirate M, et al. A potent neutralizing monoclonal antibody to human growth hormone suppresses insulin-like growth factor-1 in female rats. Endocrinology. 2024;165(5):bqae033. https://doi.org/10.1210/endocr/bqae033. · doi:10.1210/endocr/bqae033
  84. Ravel G, Gaume X, Berardet C, Chalmey C, Kurasaki H, Tomiyama T, et al. Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo. Eur J Endocrinol. 2025;192(3):299–307. · doi:10.1093/ejendo/lvaf043
  85. Allas S, Ravel G, Farrell C, Fillon S, Taha O, Culler MD, et al. A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel small peptide growth hormone receptor antagonist, in healthy subjects. J Endocr Soc. 2024;8(Supplement 1):bvae163.1100. · doi:10.1210/jendso/bvae163.1100

Metadata

Authors
Tritos, N. A., & Biller, B. M. K.
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2026-04-11
Volume
86
Issue
6
Pages
841-850
ISSN
  • 0012-6667
  • 1179-1950
DOI
10.1007/s40265-026-02312-2
Cited by
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. https://app.cochat.ai/papers/10.1007/s40265-026-02312-2
The paper
Tritos, N. A., & Biller, B. M. K. (2026). Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. Drugs. https://doi.org/10.1007/s40265-026-02312-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.